Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Shares Outstanding (Diluted Average) (2021 - 2026)

Nurix Therapeutics (NRIX) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $110.1 million as the latest value for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 31.73% to $110.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $110.1 million through Feb 2026, up 31.73% year-over-year, with the annual reading at $86.7 million for FY2025, 29.12% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $110.1 million at Nurix Therapeutics, up from $86.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $110.1 million in Q1 2026, with the low at $44.7 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $64.9 million, with a median of $54.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 1.62% in 2024, then surged 52.2% in 2025.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $48.6 million in 2022, then grew by 11.79% to $54.3 million in 2023, then increased by 23.52% to $67.1 million in 2024, then grew by 29.12% to $86.7 million in 2025, then increased by 27.01% to $110.1 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $110.1 million, $86.7 million, and $84.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.